Compassionate use of hzVSF-v13 in two patients with severe COVID-19

J Med Virol. 2020 Nov;92(11):2371-2373. doi: 10.1002/jmv.26063. Epub 2020 Jun 3.

Authors

Chang Kyung Kang¹, Pyoeng Gyun Choe¹, Sungman Park², Taek Soo Kim³, Moon-Woo Seong³, Nam-Joong Kim¹, Myoung-Don Oh¹, Wan Beom Park¹, Yoon-Won Kim²

Affiliations

¹ Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
² ImmuneMed Corporation, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use*
COVID-19 / immunology
COVID-19 / therapy*
COVID-19 Serotherapy
Compassionate Use Trials*
Humans
Immunization, Passive
Immunoglobulin G / therapeutic use*
Male
Republic of Korea
Treatment Outcome

Substances

Antibodies, Monoclonal
Antiviral Agents
Immunoglobulin G